Antiplatelet

SOLACI-SBHCI 2023 | Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel – Dr. Roxana Mehran

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Roxana...

solaci - 17 August, 2023

Learn More

Antiplatelet

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Marco...

solaci - 16 August, 2023

Learn More

Antiplatelet

Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

Secondary prevention with P2Y12 inhibitors vs aspirin monotherapy in CAD patients Antiaggregation therapy plays a central role at...

solaci - 13 July, 2023

Learn More

Antiplatelet

Abbreviated Therapy in Patients with Acute Coronary Syndrome: How Safe Is Conservative DAPT Treatment?

Abbreviated dual antiplatelet therapy in patients at high risk for bleeding and acute myocardial infarction. Patients with acute...

solaci - 1 June, 2023

Learn More

Antiplatelet

Abbreviated Antiaggregant Treatment in High Bleeding Risk Patients from the MASTER-DAPT (15-Month Followup)

Benefits of abbreviated antiaggregant treatment in high bleeding risk patients. Dual antiplatelet therapy (DAPT), established by different guidelines,...

solaci - 15 May, 2023

Learn More

Acute coronary syndromes

Rivaroxaban in Acute Coronary Syndrome

Acute coronary syndromes (ACS) involve high mortality risk, especially ST elevation ACS. Their treatment is based on...

solaci - 23 February, 2023

Learn More

Acute coronary syndromes

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies. Even though prolonged dual antiplatelet therapy (DAPT)...

solaci - 10 February, 2023

Learn More

Antiplatelet

Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?

The safety and efficacy of drug-coated balloons (DCB) has been established for the treatment of in-stent restenosis...

solaci - 7 February, 2023

Learn More

Antiplatelet

SOLACI-SBHCI 2023 | Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel – Dr. Roxana Mehran

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

Abbreviated Therapy in Patients with Acute Coronary Syndrome: How Safe Is Conservative DAPT Treatment?

Abbreviated Antiaggregant Treatment in High Bleeding Risk Patients from the MASTER-DAPT (15-Month Followup)

Rivaroxaban in Acute Coronary Syndrome

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?

Last News

Long Term Results of the International Chimney Registry

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

Institutional News

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

Check out the best images of the El Salvador 2024 Sessions

The El Salvador 2024 Sessions are coming soon

Access